Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer

Clinical Cancer Research

Volumn 5, Issue 1, 1999, Pages 9-16

  Robertson, Michael J ^a,f   Cameron, Christine ^a   Atkins, Michael B ^b   Gordon, Michael S ^c   Lotze, Michael T ^d   Sherman, Matthew L ^e   Ritz, Jerome ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e PFIZER INC   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; GAMMA INTERFERON; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; RECOMBINANT INTERLEUKIN 12;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-12; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; NEOPLASMS; RECOMBINANT PROTEINS; T-LYMPHOCYTES; UP-REGULATION;

EID: 0032900383     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Trinchieri, G. Interleukin-12: a proinflammatory cytokine with imraunoregulatory functions that bridge innate resistance and antigenspecific adaptive immunity. Annu. Rev. Immunol., 13: 251-276, 1995.
2. Hendrzak, J. A., and Brunda, M. J. Interleukin-12: biologic activity, therapeutic utility, and role in disease. Lab. Investig., 72: 619-637, 1995.
3. Gately, M. K., Wolitzky, A. G., Quinn, P. M., and Chizzonite, R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell. Immunol., 143: 127-142, 1992.
4. Gately, M. K., Warrier, R. R., Honasoge, S., Carvajal, D. M., Faherty, D. A., Connaughton, S. E., Anderson, T. D., Sarmiento, U., Hubbard, B. R., and Murphy, M. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-γ in vivo. Int. Immunol., 6: 157-167, 1994.
5. + T lymphocytes. J. Immunol., 151: 2444-2452, 1993.
6. Trinchieri, G. Interleukin-12 and its role in the generation of TH 1 cells. Immunol. Today, 14: 335-338, 1993.
7. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., and Trinchieri, G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med., 170: 827-845, 1989.
8. Chan, S. H., Perussia, B., Gupta, J. W., Kobayashi, M., Pospisil, M., Young, H. A., Wolf, S. F., Young, D., Clark, S. C., and Trinchieri, G. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of responder cells and synergy with other inducers. J. Exp. Med., 173: 869-879, 1991.
9. Robertson, M. J., Soiffer, R. J., Wolf, S. F., Manley, T. J., Donahue, C., Young, D., Hermann, S. H., and Ritz, J. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells is differentially regulated by NKSF. J. Exp. Med., 175: 779-788, 1992.
10. + NK cells. J. Immunol., 148: 2429-2436, 1992.
11. Chehimi, J., Valiante, N. M., D'Andrea, A., Rengaraju, M., Rosado, Z., Kobayashi, M., Perussia, B., Wolf, S. F., Starr, S. E., and Trinchieri, G. Enhancing effect of natural killer cell stimulatory factor (NKSF/ interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells. Eur. J. Immunol., 23: 1826-1830, 1993.
12. Lieberman, M. D., Sigal, R. K., Williams, N. N., II, and Daly, J. M. Natural killer cell stimulatory factor (NKSF) augments natural killer cell and antibody-dependent fumoricidal responses against colon carcinoma cell lines. J. Surg. Res., 50: 410-415, 1991.
13. Hall, S. S. IL-12 at the crossroads. Science (Washington DC), 268: 1432-1434, 1995.
14. Brunda, M. J., and Gately, M. K. Interleukin-12: potential role in cancer therapy. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Important Advances in Oncology 1995, pp. 3-18. Philadelphia: J. B. Lippincott, 1995.
15. Robertson, M. J., and Ritz, J. Interleukin 12: basic biology and potential applications in cancer treatment. The Oncologist, 1: 93-102, 1996.
16. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., and Gately, M. K. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med., 178: 1223-1230, 1993.
17. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., and Lotze, M. T. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol., 153: 1697-1706, 1994.
18. Zou, J-P., Yamamoto, N., Fujii, T., Takenaka, H., Kobayashi, M., Herrmann, S. H., Wolf, S. F., Fujiwara, H., and Hamaoka, T. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-rumor T cells. Int. Immunol., 7: 1135-1145, 1995.
19. Mu, J., Zou, J-P., Yamamoto, N., Tsutsui, T., Tai, X-G., Kobayashi, M., Herrmann, S., Fujiwara, H., and Hamaoka, T. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res., 55: 4404-4408, 1995.
20. Soiffer, R. J., Robertson, M. J., Murray, C., Cochran, K., and Ritz, J. Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood, 82: 2790-2796, 1993.
21. Rossi, A. R., Pericle, F., Rashleigh, S., Janiec, J., and Djeu, J. Y. Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood, 83: 1323-1328, 1994.
22. Andrews, J. V. R., Schoof, D. K., Bertagnolli, M. M., Peoples, G. E., Goedegebuure, P. S., and Eberlein, T. J. Immunomodulatory effects of interleukin-12 on human tumor-infiltrating lymphocytes. J. Immunother., 14: 1-10, 1993.
23. Zeh, H. J., III, Hurd, S., Storkus, W. J., and Lotze, M. T. Interleukin-12 promotes the proliferation and cytolytic activity of immune effectors: implications for the immunotherapy of cancer. J. Immunother., 14: 155-161, 1993.
24. Sykes, M., Szot, G. L., Nguyen, P. L., and Pearson, D. A. Interleukin-12 inhibits murine graft-versiw-host disease. Blood, 86: 2429-2438, 1995.
25. Yang, Y-G., Sergio, J. J., Pearson, D. A., Szot, G. L., Shimizu, A., and Sykes, M. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CDS T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood, 90: 4651-4660, 1997.
26. Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., III, McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., and Lotze, M. T. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol., 154: 6466-6474, 1995.
27. Meko, J. B., Yim, J. H., Tsung, K., and Norton, J. A. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res., 55: 4765-4770, 1995.
28. Colombo, M. P., Vagliani, M., Spreafico, F., Parenza, M., Chiodoni, C., Melani, C., and Stoppacciaro, A. Amount of interleukin-12 available at the tumor site is critical for tumor regression. Cancer Res., 56: 5231-5234, 1996.
29. Atkins, M. B., Robertson, M. J., Gordon, M., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D., Garzone, P. D., Mier, J. W., Canning, C. M., Battiato, L., Tahara, H., and Sherman, M. L. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res., 3: 409-417, 1997.
30. Robertson, M. J., Caligiuri, M. A., Manley, T. J., Levine, H., and Ritz, J. Human natural killer cell adhesion molecules: differential expression after activation and participation in cytolysis. J. Immunol., 145: 3194-3201, 1990.
31. Pross, H. F., Callewaert, D., and Rubin, P. Assays for NK cell cytotoxicity: their values and pitfalls. In: E. Lotzova and R. B. Herberman (eds.), Immunobiology of Natural Killer Cells, pp. 2-20. Boca Raton, FL: CRC Press, 1986.
32. Leonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., and Ryan, J. L. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood, 90: 2541-2548, 1997.
33. Rabinowich, H., Herberman, R. B., and Whiteside, T. L. Differential effects of IL12 and IL2 on expression and function of cellular adhesion molecules on purified human natural killer cells. Cell. Immunol., 752: 481-498, 1993.
34. Robertson, M. J., and Ritz, J. Biology and clinical relevance of human natural killer cells. Blood, 76: 2421-2438, 1990.
35. Baxevanis, C. N., Reclos, G. J., Gritzapis, A. D., Dedousis, G. V. Z., Missitzis, I., and Papamichail, M. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer (Phila.), 72: 491-501, 1993.
36. Gately, M. K., Desai, B. B., Wolitzky, A. G., Quinn, P. M., Dwyer, C. M., Podlaski, F. J., Familletti, P. C., Sinigaglia, F., Chizzonite, R., Gubler, U., and Stem, A. S. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol., 147: 874-882, 1991.
37. + T lymphocytes, and NK cells. J. Immunol., 149: 3495-3502, 1992.
38. Bajetta, E., Vecchio, M. D., Mortarini, R., Nadeau, R., Rakhit, A., Rimassa, L., Fowst, C., Borri, A., Anichini, A., and Parmiani, G. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin. Cancer Res., 4: 75-85, 1998.
39. Brunda, M. J., Luistro, L., Hendrzak, J. A., Fountoulakis, M., Garotta, G., and Gately, M. K. Role of Interferon-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother., 17: 71-77, 1995.
40. Aste-Amezaga, M., D'Andrea, A., Kubin, M., and Trinchieri, G. Co-operation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell. Immunol., 756: 480-492, 1994.
41. Lotze, M. T., Matory, Y. L., Ettinghausen, S. E., Rayner, A. A., Sharrow, S. O., Seipp, C. A. Y., Custer, M. C., and Rosenberg, S. A. In vivo administration of purified human interleukin 2. II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol., 135: 2865-2875, 1985.
42. Bich-Thuy, L. T., Dukovich, M., Peffer, N. J., Fauci, A. S., Kehrl, J. H., and Greene, W. C. Direct activation of human resting T cells by IL 2: the role of an IL 2 receptor distinct from the Tac protein. J. Immunol., 739: 1550-1556, 1987.
43. Trinchieri, G., Matsumoto-Kobayashi, M., Clark, S. C., Seehra, J., London, L., and Perussia, B. Response of resting human peripheral blood natural killer cells to interleukin 2. J. Exp. Med., 160: 1147-1169, 1984.
44. Savary, C. A., and Lotzova, E. Adhesion molecules on MHCnonrestricted lymphocytes: high density expression and role in oncolysis. Lymphokuie Cytokine Res., 11: 149-156, 1992.
45. Springer, T. A. Adhesion receptors of the immune system. Nature (Lond.), 346: 425-434, 1990.
46. Lanier, L. L., and Hemperly, J. J. CD56 and CD57 cluster workshop report. In: S. F. Schlossman, L. Boumsell, W. Gilks, J. M. Harlan, T. Kishimoto, C. Morimoto, J. Ritz, S. Shaw, R. Silverstein, T. Springer, T. F. Tedder, and R. F. Todd (eds.), Leucocyte Typing V: White Cell Differentiation Antigens, pp. 1398-1400. Oxford, United Kingdom: Oxford University Press, 1995.
47. Zocchi, M. R.,and Poggi, A. Human γδ T lymphocytes use N-CAM to interact with the subendothelial matrix. J. Natl. Cancer Inst., 87: 846-847, 1995.
48. Kohl, S., Sigaroudinia, M., Charlebois, E. D., and Jacobson, M. A. Interleukin-12 administered in vivo decreases human NK cell cytotoxicity and antibody-dependent cellular cytotoxicity to human immunod-eficiency virus-infected cells. J. Infect. Dis., 174: 1105-1108, 1996.
49. Wigginton, J. M., Komschlies, K. L., Back, T. C., Franco, J. L., Brunda, M. J., and Wiltrout, R. H. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst., 88: 38-43, 1996.
50. Alexander, J. P., Kudoh, S., Melsop, K. A., Hamilton, T. A., Edinger, M. G., Tubbs, R. R., Sica, D., Tuason, L., Klein, E., Bukowski, R. M., and Finke, J. H. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res., 53: 1380-1387, 1993.
51. Al-Sarraf, M., Sardesai, S., and Vaitkevicius, V. K. Clinical immunologic responsiveness in malignant disease. II. In vitro lymphocyte response to phytohemagglutinin and the effect of cytotoxic drugs. Oncology (Basel), 26: 357-368, 1972.
52. Whittaker, M. G., Rees, K., and Clark, C. G. Reduced lymphocyte transformation in breast cancer. Lancet, 1: 892-893, 1971.
53. 1ck in T-cells infiltrating human renal cell carcinoma. Cancer Res., 53: 5613-5616, 1993.
54. Nakagomi, H., Petersson, M., Magnusson, I., Juhlin, C., Matsuda, M., Mellstedt, H., Taupin, J-L., Vivier, E., Anderson, P., and Kiessling, R. Decreased expression of signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res., 53: 5610-5612, 1993.
55. Sacco, S., Heremans, H., Echtenacher, B., Buurman, W. A., Amraoui, Z., Goldman, M., and Ghezzi, P. Protective effect of single interleukin-12 (IL-12) predose against the toxicity of subsequent chronic IL-12 in mice: role of cytokines and glucocorticoids. Blood, 90: 4473-4479, 1997.